Clinical Trial Update: Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating sintilimab plus stereotactic body radiotherapy as neoadjuvant therapy for resectable hepatocellular carcinoma with por…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: West China Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING